Eisai Inc.

NEWS

Merck's Cyber Attack Could Cost Insurers $275M

FDA Grants Merck’s Keytruda Priority Review for Cervical Cancer

The FDA accepted Merck & Co.’s supplemental Biologics License Application and granted Priority Review for Keytruda in advanced cervical cancer.

March 13, 2018

3 min read

Mark Terry

Eisai to Present Latest Data on Perampanel and Rufinamide at 71st American Epilepsy Society Annual Meeting

Inovelon will be presented at the 71st AES Annual Meeting to be held from December 1 to 5, 2017 in Washington D.C. in the United States.

November 27, 2017

2 min read

JOBS

IN THE PRESS

Press Releases

Eisai Deepens Body of Clinical Evidence for LENVIMA (Lenvatinib) Across Established Indications at ASCO 2026

May 20, 2026

26 min read

Press Releases

Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s Disease

May 8, 2026

18 min read

Press Releases

Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)

April 21, 2026

19 min read

Press Releases

Eisai to Present the Latest Data on Real-World Treatment with Lecanemab and Supporting a Standardized Framework for Treating Early Alzheimer’s Disease at the 78th American Academy of Neurology’s Annual Meeting

April 9, 2026

10 min read

Press Releases

Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency

March 27, 2026

14 min read

Press Releases

EISAI TO BEGIN ENROLLING PHASE 2 STUDY IN PATIENTS WITH NARCOLEPSY

March 26, 2026

3 min read

Press Releases

Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026

March 22, 2026

16 min read

Press Releases

Excalipoint Therapeutics Launches with $68.7 Million to Develop Next-Generation T-Cell Engager Therapies

March 18, 2026

6 min read

Press Releases

Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD™ 2026 Annual Meeting

March 11, 2026

7 min read

Press Releases

Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

March 3, 2026

21 min read